Replimune stock.

Nov 8, 2023 · Our Science. Cancer involves a failure of the immune system in one of two ways: 1) the immune system is unable to recognize the tumor as foreign, and/or 2) the immune response is disabled or shut down by the tumor. Replimune is pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter ... Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class ...Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]

Earnings announcements can affect a stock's price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...Dec 9, 2022 · In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ...

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

Nov 24, 2023 · The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ... May 18, 2023 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... The Replimune Group Inc. stock price fell by -1.82% on the last day (Wednesday, 29th Nov 2023) from $11.53 to $11.32.During the last trading day the stock fluctuated 6.13% from a day low at $11.26 to a day high of $11.95.The price has been going up and down for this period, and there has been a 0.89% gain for the last 2 weeks.15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies.

During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.83 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $11.71, reflecting an intraday gain of 4.74% or $0.53. The 52-week high for the REPL share is $29.52, that puts it down -152.09 from that peak ...

In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ...

A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …REPL News. This page features the latest news about the Replimune stock. Replimune earnings missed by $0.09, revenue was in line with estimates. By Investing.com. • Nov 07, 2023. Replimune ...11.32. -0.21. -1.82%. WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio ...Our Science. Cancer involves a failure of the immune system in one of two ways: 1) the immune system is unable to recognize the tumor as foreign, and/or 2) the immune response is disabled or shut down by the tumor. Replimune is pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter ...

8 Jun 2020 ... * REPLIMUNE GROUP - PROPOSED OFFERING ALSO OF PRE-FUNDED WARRANTS TO PURCHASE SHARES OF STOCK, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis. WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed ...PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …29 Jun 2020 ... The offering consisted of shares of Replimune's common stock and pre‑funded warrants to acquire shares of its common stock. The shares were ...PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Replimune Group Stock (NASDAQ: REPL) stock price, news, charts, stock research, profile.

WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or ...

Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Replimune Group Inc stock price live 11.21, this page displays NASDAQ REPL stock exchange data. View the REPL premarket stock price ahead of the market session or assess the after hours quote.Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping ...Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock.At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...Find out all the key statistics for Replimune Group, Inc. (REPL), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. ... Stock Price History ...Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m... The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ...

Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.

Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...

18 Sep 2023 ... at Replimune and Gilead also shared how they're accelerating ... Veeva (VEEV stock) Exceptional Business! SaaS Growth Stock for Life Sciences ...Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.Replimune Group, Inc. Common Stock (REPL) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is...REPL Replimune Group Inc Nov 24 • 01:26PM ET 10.85 +0.56 5.49% Healthcare • Biotechnology • USA • NASD Stock Detail • Compare Perf. • Options Chain …Report of unscheduled material events or corporate event. 8-K. 0001104659-23-115027.pdf. 0001104659-23-115027.rtf. 0001104659-23-115027.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 07, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q.Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%. Replimune stock price has been receiving support from the successful results of the Phase 1 clinical trial of RP1 and RP2 in patients with solid tumors.Dec 4, 2023 · Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08. Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Fiscal Q2 2024 ended 9/30/23. Get the latest Replimune Group Inc (REPL) real-time quote, historical performance, charts, and other financial information to help you make more …

Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ...A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Mutual fund, Stake, Shares owned, Total value ($), Shares bought / sold, Total change. T Rowe Price New Horizons Fund, 4.14%, 2,444,774, 35,620,357, -840 ...Instagram:https://instagram. block buster stocknaples home insurancebtcc app reviewnationwide insurance motorcycle What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ...14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ... apple predictionscommercial real estate crowd funding Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M.Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ... amt ticker symbol BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …